The Sputnik V COVID-19 Vaccine under emergency use can reduce risk against symptomatic COVID-19 for priority groups aged 18 and older, HTAC notes in a recent recommendation

Gamaleya COVID-19 Vaccine under Emergency Use

 The emergency use authorization of the Food and Drug Administration (FDA) (dated 19 March 2021)  allows for timely access of COVID-19 vaccines for Filipinos during the pandemic.  This assures the public that the COVID-19 vaccine has passed the quality, safety, and efficacy criteria. Nevertheless, studies are continuing to determine its long-term efficacy and safety and its potential to reduce COVID-19 transmission.

How does Gamaleya COVID-19 Vaccine work?

Sputnik V COVID-19 Vaccine uses a weakened common cold virus (called adenovirus) as carrier of the instructions for our cells to make the “spike protein” unique to SARS-CoV-2. In teaching the cells to make specific parts of coronavirus, these vaccines allow our bodies to detect them, produce antibodies, and fight off future infection. 

Why is Gamaleya recommended by HTAC?

Current available data suggests Sputnik V COVID-19 Vaccine can prevent symptomatic COVID-19 for persons aged 18 and older.

Compared to previous non-COVID vaccines, health experts have noted few reported side effects, with no serious injuries or deaths from vaccination. 

Based on existing evidence from ongoing trials, the HTAC considers that the vaccine’s positive health impacts outweigh its short-term risks. 

Other factors informing the HTAC recommendation include potential health, economic, and social benefits in recommending Sputnik V COVID-19 Vaccine. 

As new information emerges, the Council will continue to update its recommendations and provide our policy-makers, health providers, and the Filipino public evidence-based guidance.

Guidance for Health Care Providers:

Evidence summary